"To treat recalcitrant skin conditions such as atopic dermatitis and hand eczema, a comprehensive and long term solution is required to address the underlying issue of a compromised skin barrier while reducing inflammation," said Dr. Christopher N. Hensby, Senior Vice President of Quinnova Pharmaceuticals. First and foremost, Neosalus helps to restore a dysfunctional skin barrier by replenishing the lost lipids, thereby decreasing trans-epidermal water loss (TEWL). Furthermore, Neosalus functions as a protectant to reduce the penetration of irritants from further exacerbating the itch and scratch cycle. Finally, Neosalus has anti-inflammatory ability that helps to reduce the frequency and severity of flare-ups, thus making it a steroid sparing and complementary treatment to other concomitant treatments.

In addition to the therapeutic benefits of Neosalus, patients will likely appreciate the cosmetic elegance of Proderm Technology ^TM. Unlike some creams and lotions which have a tendency to leave the skin feeling greasy after application, Neosalus, a water-lipid based foam, absorbs quickly, spreads easily, and is non-greasy. Patients can resume their work and daily activities immediately after applying Neosalus, thus enhancing compliance and maximizing treatment results.

Quinnova Pharmaceuticals' sales force calls on dermatologists across the United States.

About Quinnova Pharmaceuticals, Inc.

Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative topical drug delivery platforms. For more information, please visit www.quinnova.com.